Sirolimus (Rapamycin) and Aging
Aging
Why should I take this course?
-
Review mechanisms for aging as a whole and age-related diseases broadly -
Briefly review the landscape of pharmaceutical interventions for age-related diseases (ex: metformin)
-
Discuss proposed mechanisms of action of sirolimus (rapamycin) for mitigation of age-related diseases
-
Evaluate data thus far from completed animal and human trials on sirolimus (rapamycin) and aging as well as safety
-
Discuss planned RAPID clinical trial and why the study was designed in the way that it is
Course Lessons
Dr. Jonathan An
Dr. Jonathan An is an Assistant Professor and Assistant Graduate Program Director in Oral Health Sciences at the University of Washington School of Dentistry, as well as a practicing dentist in Mill Creek, Washington. He earned his DDS and PhD from the University of Washington, where he studied the biological mechanisms of aging in oral biology. His lab was among the first to show the effects of oral rejuvenation by targeting aging processes.
Dr. An leads a pioneering human clinical trial to evaluate mTOR pathway targeting for improving periodontitis in older adults, holding the only FDA IND approval for such a trial. His research spans various animal models, including worms, mice, rats, and non-human primates. He integrates modern technology in his private practice, offering services like same-day crowns, clear aligner therapy, and restorative and implant dentistry.